New VETCOP study measures steroid hesitancy in canine atopy care

Version 1

A new study in Veterinary Dermatology suggests that fear of topical steroid treatment is common among pet parents managing canine atopic dermatitis, and that this concern may be undermining adherence to care. The researchers, working across China and Singapore, adapted the human dermatology TOPICOP questionnaire into a veterinary version called VETCOP and used it to survey 363 pet parents of dogs with canine atopic dermatitis. Their conclusion: topical corticosteroid phobia appears to be a meaningful barrier to treatment, and veterinarians have a central role in explaining how these drugs are used, what risks are real, and how to use them safely. (researchgate.net)

Why it matters: Canine atopic dermatitis is common, chronic, and often needs long-term management built around flare control, skin barrier support, and pet parent adherence. International guidance has long supported topical glucocorticoids as an effective option for localized lesions and short-term flare treatment, while also stressing tailored dosing and monitoring for adverse effects such as skin atrophy with prolonged daily use. If pet parents are reluctant to start, continue, or correctly apply these medications, treatment failure may reflect communication gaps as much as drug performance. That makes education, expectation-setting, and follow-up part of the therapy itself. (bmcvetres.biomedcentral.com)

What to watch: Watch for follow-on work validating VETCOP in other markets and linking phobia scores to real-world adherence, outcomes, and consultation strategies. (researchgate.net)